CR-CP Life Science Fund has led the RSV treatment producer’s latest round, participating alongside new and returning backers including Novo and EMS.
UK-based respiratory virus therapy developer ReViral closed a $44m series C round on Tuesday led by CR-CP Life Science Fund, an investment vehicle for conglomerates China Resources and Charoen Pokphand Group.
Pharmaceutical firms Novo Holdings and EMS also took part in the round, the latter through its Brace Pharmaceuticals unit, as did Andera Partners, Green Sands Equity, New Leaf Venture Partners, OrbiMed Advisors and Perceptive Advisors.
Founded in 2011, ReViral is working on antiviral medicines for respiratory syncytial virus (RSV),…
